Author: Vivian Xie 25th June 2026

The Association of Southeast Asian Nations (ASEAN) represents one of the world's most dynamic pharmaceutical markets, with explosive growth creating unprecedented new opportunities for the pharma sector. However, achieving true success in the region demands a comprehensive understanding of its myriad regulations, many of which change across its ten member states - Brunei, Cambodia, Indonesia, Laos, Malaysia, Myanmar, the Philippines, Singapore, Thailand and Vietnam.

Companies looking to access the regional market will need to undertake complex work to guarantee harmonisation across ASEAN. Products must navigate multiple regulatory pathways with varying documentation requirements, approval timelines, and post-market obligations. According to DIA Global Forum's analysis [1] of regulatory harmonisation, the Pharmaceutical Product Working Group (PPWG) has been established under the ASEAN Consultative Committee for Standards and Quality (ACCSQ), supporting the reduction of technical trade barriers and improving access to pharmaceutical products without compromising safety.

The results of these initiatives include developing the ASEAN Sectoral Mutual Recognition Agreement (MRA) on Good Manufacturing Practice (GMP) Inspection for Manufacturers of Medicinal Products, the Post Market Alert System (PMAS), the ASEAN Common Technical Dossier (ACTD), ASEAN Common Technical Requirements (ACTR), and the ASEAN MRA for Bioequivalence Study Reports of Generic Medicinal Products. These initiatives are in differing stages of implementation, and comprise a combination of voluntary measures and obligatory requirements – all in the name of streamlining international companies’ access to the ASEAN market.

How the ASEAN Is Coming Together to Steer Progress

The ASEAN Common Technical Dossier (ACTD), introduced in 2006, represents a cornerstone of the region’s efforts in harmonisation. As Pharma Regulatory [2] notes, the ACTD has standardised the documentation requirements across ASEAN member states, providing a common format for pharmaceutical product registration applications. The ACTD was developed using the ICH Common Technical Document (CTD) as a model, but has adapted its structure to match ASEAN market realities.

As the majority of pharmaceuticals registered in ASEAN are generics, and health authorities mainly review the quality module, the ACTD uses consolidate quality data under a single module to facilitate review. Some member states have mandated ACTD for any new submissions since 2008, whilst others still accept its predecessor, ICH-CTD, as an alternative. Which goes to say that implementation is still inconsistent across the region. IPQ analysis [3]states that not all ASEAN countries are required to adopt ACTD format, and this variability means pharmaceutical companies must assess each of their target market’s requirements before adopting a more uniform approach.

Navigating National Variations in Packaging and Labelling Requirements

Whilst ACTD harmonisation addresses registration dossier format, the compliance requirements for pharma packaging in Asia remain largely country-specific, creating significant complexity for companies seeking regional distribution. Each ASEAN member state maintains its own distinct packaging and labelling requirements covering everything from language specifications and manufacturer information to font size and type. Some, like Malaysia’s, have been in place for over 40 years, while others have been under far more recent review.

For example, requirements for Chinese proprietary medicines are separately set out under the Medicines (Labelling of Chinese Proprietary Medicines) Regulations, demonstrating the specificity that characterises ASEAN packaging regulations. Non-compliance with these continuing obligations constitutes an offence under Singapore's Health Products Act, attracting fines and imprisonment.

Meanwhile, Thailand's regulatory environment has evolved significantly in this year alone. According to industry reports, [4] Thailand's February 2026 update represents the most significant regulatory change in the region. The Thai FDA's draft regulation expands scope from ceramics to include metals, glass and paper materials, with key provisions including prohibition of BPA (limit of detection 1 µg/kg), PFAS concentration limits of 25ppb, mandatory food-grade colourants and prohibition of container reuse. The transition period ranges from 2 to 5 years depending on material category, giving suppliers time to reformulate and retest products.

Implementing Track-and-Trace for Pan-Asian Pharmaceutical Serialisation

The pharma serialisation requirements across ASEAN markets represent one of the most significant compliance challenges the region faces. Multiple countries have implemented their own track-and-trace systems to combat counterfeiting, but timelines, technical requirements and enforcement approaches vary substantially across each territory

According to VISIOTT's analysis, [5] the Asia-Pacific is making significant progress in implementing track-and-trace regulations, particularly key markets such as Malaysia, Indonesia, Thailand and Vietnam. Governments and regulatory bodies in these countries are enhancing supply chain visibility by prioritising the development of stringent compliance frameworks to enhance supply chain transparency. By adopting advanced serialisation and traceability technologies, businesses will be better equipped to meet regulatory requirements and maintain operational efficiency.

China's Advanced Track-and-Trace System

China has established one of the world's most comprehensive pharmaceutical traceability systems, governed by the China Food and Drug Administration (CFDA) through the China Work Plan for Pharmaceutical Electronic Monitoring and 2019 Drug Administration Law. These requirements have been meticulously designed to ensure the integrity of medicinal products across the supply chain, with mandatory serialisation for prescription drugs and comprehensive data reporting requirements.

Indonesia's TTAC Framework

Indonesia's National Agency of Drug and Food Control (BPOM) has established one of Southeast Asia's most comprehensive pharmaceutical traceability systems through its Track and Trace Anti-Counterfeit (TTAC) framework. This robust regulatory mandate demonstrates Indonesia's commitment to combating counterfeit medicines, enhancing supply chain transparency and safeguarding public health across its vast archipelago nation. The TTAC system requires all pharmaceutical packaging to display unique serialisation codes, with the data uploaded to a central government database to enable real-time verification and supply chain monitoring.

India's Evolving Requirements

India's pharmaceutical industry is governed by various regulatory bodies, making adherence to traceability standards crucial in ensuring the safety and integrity of medicines. India has mandatory testing requirements at the time of import of first commercial shipment, with subsequent testing conducted according to defined schedules: every imported batch of vaccines and plasma-derived requires testing, while biologics are only tested once every six months.

Japan's Electronic Package Insert System

Japan has pioneered a transformative approach to pharmaceutical tracking and traceability through its mandatory Electronic Package Insert (EPI) system. Since August 2021, the country’s regulatory framework has fundamentally shifted from traditional paper-based documentation to a comprehensive digital ecosystem that ensures real-time access to critical product information whilst maintaining robust traceability throughout the pharmaceutical supply chain.

GMP Mutual Recognition: Facilitating Regional Trade

In accordance with the ASEAN Pharmaceutical Regulatory Partnership document, [7] all ASEAN Member States have signed a mutual recognition agreement for Good Manufacturing Practice inspections. This enables regulatory authorities to recognise GMP inspection reports from other member states, reducing duplicative inspections and accelerating market access for compliant manufacturers.

The GMP MRA creates tangible benefits for pharmaceutical manufacturers operating across multiple ASEAN markets. Rather than undergoing separate inspections by each national regulatory authority, manufacturers can leverage inspection reports from one ASEAN member state to support its applications in others. This reduces compliance costs, accelerates approval timelines and eliminates redundant audits that consume regulatory and industry resources.

However, not all ASEAN member states have yet put the MRA framework into full operation, with some nations continuing to require country-specific inspections despite the agreement. Additionally, the MRA applies primarily to finished pharmaceutical products, with active pharmaceutical ingredient (API) manufacturers often subject to separate legislation.

Sustainability and Environmental Compliance

Environmental regulations are becoming increasingly influential on the pharma packaging landscape, and several ASEAN countries have begun implementing restrictions on packaging materials, recycling mandates and extended producer responsibility (EPR) schemes. Governments and regulators across the region are putting stricter rules in place regarding plastic waste, recycling and carbon emissions, requiring packaging companies to shift to green materials. However, pharmaceutical packaging must provide high protective barriers, sterilisation compatibility and chemical stability, which often depend on multilayer plastics and aluminium-based materials that are difficult to recycle.

Mordor Intelligence reports [8] that environmental regulations in Japan and South Korea require elimination of PVC in blisterpacks by 2027-2028. Converters will need to re-engineer tooling as polypropylene and polyester films require new sealing windows and cavity geometries, leading to validation-related expenses that could reach half a million US dollars per SKU. Likewise, drug formulators may need moisture scavengers, which can delay launches and complicate stability programmes.

Thailand is pursuing Extended Producer Responsibility (EPR) packaging and strengthening regulations around circular packaging; with a pilot currently being conducted in Chonburi, the country is aiming for more widespread adoption by 2027. According to the proposed laws around sustainable packaging, these changes will transfer accountability for post-consumer packaging waste to manufacturers and importers. Additionally, Thailand advanced its plan for managing plastic waste, which includes banning imports of plastic waste as of January 2025.

Singapore as the Regional Hub for Regulation

Long positioned as the ASEAN's regulatory leader, Singapore stands out as the ideal location for pharmaceutical companies to begin their quest for regional market access. According to comprehensive regulatory guidance, [9] Singapore’s rigorous drug registration framework is overseen by its Health Sciences Authority, which is responsible for evaluating, approving and regulating all therapeutic products before they can be supplied in the country.

The HSA's efficiency, transparency, and science-driven evaluations have earned global recognition, with the agency almost single-handedly fostering Singapore's position as a hub for Asian biomedical innovation. For multinational pharmaceutical companies, obtaining HSA approval provides access not only to Singapore's market but also to broader ASEAN markets, where Singapore often acts as a regulatory benchmark.

The HSA regulatory framework is built on Singapore's Health Products Act and related regulations whilst aligning with global standards including WHO prequalificationx. Through regional and global partnerships, HSA facilitates reliance on decisions from trusted regulators such as the FDA and EMA, significantly reducing approval timelines and enhancing efficiency for multinational sponsors.

For reliance pathways, timelines can be reduced significantly, allowing approvals within 90-120 working days. This positions Singapore as one of the most efficient regulators in Asia, making it an attractive first-market entry point for companies seeking broader ASEAN access.

Building Regulatory Excellence for ASEAN Success

As we’ve outlined, there are a number of steps companies need to take in order to successfully navigate ASEAN pharmaceutical regulations. Those who have broken into the market have done so by adopting several best practices:

Early Regulatory Engagement – Proactive consultation with regulatory authorities during product development enables identification of potential compliance issues before they delay approvals. Many ASEAN regulatory authorities offer pre-submission meetings where companies can discuss product classification, documentation requirements and approval pathways.

Harmonised Packaging Design – Where possible, designing packaging that meets requirements across multiple ASEAN markets reduces complexity and costs. This requires careful analysis of country-specific requirements to identify common elements and unavoidable variations.

Robust Quality Management Systems – Comprehensive quality systems ensuring packaging compliance, change control, deviation management and continuous improvement provide the foundation for regulatory success. These systems must address both manufacturing quality and regulatory compliance documentation.

Technology-Enabled Compliance – Digital platforms supporting artwork management, regulatory submission tracking, serialisation data management and compliance monitoring improve efficiency whilst reducing errors. These systems become increasingly critical as companies expand across multiple ASEAN markets.

Expert Partnership Networks – Relationships with regulatory consultants, testing laboratories, packaging suppliers and technology providers who understand ASEAN requirements enable companies to access specialised expertise without maintaining all capabilities internally.

The Path Forward

Against this backdrop of regulatory complexity, harmonisation progress and evolving compliance requirements, Pharmapack Asia 2026 emerges as the essential platform for pharmaceutical packaging professionals navigating ASEAN pharmaceutical regulations. The event's dedicated regulatory zone and expert programming address the specific compliance challenges facing pharmaceutical companies, packaging manufacturers and service providers operating across the region.

As ASEAN pharmaceutical markets continue their rapid growth, regulatory compliance excellence has evolved from a necessary cost of doing business to a source of competitive advantage. Companies that master ASEAN pharmaceutical regulations can launch products faster, access more markets efficiently, reduce compliance costs through harmonised approaches and build stronger relationships with regulatory authorities.